Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to 'The Environmental Enteric Dysfunction Biopsy Initiative (EEDBI) Consortium: mucosal investigations of EED' [The American Journal of Clinical Nutrition. 2024; 120S1: S4-S14].

The American journal of clinical nutrition·2026
Same author

<i>Clostridioides difficile</i> Colonization and Infection in Pediatric Oncology and Stem Cell Transplant Patients.

Open forum infectious diseases·2026
Same author

Shiga Toxin-Producing Escherichia coli Outbreak in Canadian Daycare Centers.

JAMA network open·2026
Same author

Polygenic risk scores and HLA class II variants are biomarkers of corticosteroid response in childhood nephrotic syndrome.

Kidney international·2026
Same author

Parental obesity and risk of metabolic dysfunction associated steatotic liver disease in adult offspring: UK birth cohort study.

Gut·2026
Same author

Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome.

medRxiv : the preprint server for health sciences·2025
Same journal

Beyond consent: community engagement, benefit sharing and reciprocity in kidney genomics research.

Nature reviews. Nephrology·2026
Same journal

The social needs of patients with kidney failure.

Nature reviews. Nephrology·2026
Same journal

Long-term kidney protection in IgA nephropathy with atrasentan.

Nature reviews. Nephrology·2026
Same journal

Benefits of finerenone treatment across chronic kidney disease aetiologies.

Nature reviews. Nephrology·2026
Same journal

The versatile roles of long non-coding RNAs in kidney disease.

Nature reviews. Nephrology·2026
Same journal

Sequential therapeutic approach for the management of osteoporosis in people with chronic kidney disease.

Nature reviews. Nephrology·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Therapy: Azithromycin and decolonization after HUS

Michael E Seifert, Phillip I Tarr

    Nature Reviews. Nephrology
    |May 3, 2012
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
    09:34

    An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

    Published on: August 16, 2021

    Related Experiment Videos

    Last Updated: May 22, 2026

    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
    12:58

    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

    Published on: May 25, 2017

    An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
    09:34

    An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

    Published on: August 16, 2021